Top

Journal of Neurology

Published in:

01-03-2017 | Letter to the Editors

Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis

Authors: Felix C. Ng, James Bice, Anne Rodda, Matthew Lee-Archer, Douglas E. Crompton

Published in: Journal of Neurology | Issue 3/2017

Excerpt

Dear Sirs, …

Demaerschalk BM, Kleindorer DO, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy El Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE, American Heart Association Stroke Council and Council on Epidemiology and Prevention (2016) Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke. Stroke 47:581–641CrossRefPubMed

Diener HC, Bernstein R, Butcher K, Campbell B, Cloud G, Davalos A, Davis S, Ferro JM, Grond M, Krieger D, Ntaios G, Slowik A, Touzé E (2016) Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion. Int J Stroke 12:9–12CrossRefPubMed

Berrouschot J, Stoll A, Hogh T, Eschenfelder CC (2016) Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke 47:1936–1938CrossRefPubMed

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Jam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520CrossRefPubMed

Schmohl M, Glund S, Harada A, Imazu S, De Smet M, Moschetti V, Ramael S, Ikushima I, Grünenfelder F, Reilly P, Stangeri J (2016) Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers. Thromb Haemost. doi:10.1160/TH16-05-0385 PubMed

Schafter N, Muller A, Wullner U (2016) Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab – a case report. J Stroke Cerebrovasc Dis 25:e126–e127CrossRef

Kafke W, Kraft P (2016) Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a case report. Case Rep Neurol 8:140–144CrossRefPubMedPubMedCentral

Schulz JG, Kreps B (2016) Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke. J Neurol Sci 370:44CrossRefPubMed

Mutzenbach JS, Pikija S, Otto F, Halwachs U, Weymayr F, Sellner J (2016) Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab–a case report. Ann Clin Transl Neurol 3:889–892CrossRefPubMedPubMedCentral

10.

Gawehn A, Ayari Y, Heuschkel C, Kaste M, Kermer P (2016) Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report. J Med Case Rep 10:269CrossRefPubMedPubMedCentral

11.

Zhang J, Yang Y, Sun J, Xing Y (2014) Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med 2:81PubMedPubMedCentral

12.

Ay H, Gungor L, Arsava EM, Rosand J, Vangel M, Benner T, Schwamm LH, Furie KL, Koroshetz WJ, Sorensen AG (2010) A score to predict early risk of recurrence after ischemic stroke. Neurology 72:128–135CrossRef

Title: Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis
Authors: Felix C. Ng
James Bice
Anne Rodda
Matthew Lee-Archer
Douglas E. Crompton
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 3/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-017-8410-6

ACC 2024 Congress

Springer Medicine

Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis

Excerpt

ACC 2024 Congress

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2017

Dystonia: opportunities to gain insights into underlying pathophysiological mechanisms

Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography

Longitudinal multi-modal neuroimaging in opsoclonus–myoclonus syndrome

Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis

Identification of secondary vestibulo-ocular neurons in human based on their histochemical characteristics found in monkey

High-sensitivity cardiac troponin I and NT-proBNP as predictors of incident dementia and Alzheimer’s disease: the FINRISK Study